BIOD: Biodel Inc. Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 10, 1:02 PM Biodel (BIOD +2.2%) rises on an upgrade to Buy from Neutral at Ladenburg Thalmann (price target $6). The stock has trended higher this month as the company readies top line results (due Q3) for a Phase 2 trial of BIOD-123, one of a few candidates investors hope will help spark a resurgence for the company after the disappointing rejection of Linjeta in November of 2010. (earnings, CC) Comment! [Healthcare, On the Move]
Wednesday, May 8, 9:06 AM Biodel (BIOD) rises 6% premarket after reporting a narrower than expected Q2 loss. In its report, BIOD says fifty percent of those enrolled in a Phase 2 trial of BIOD-123 (a rapid-acting formulation of recombinant human insulin) have completed the study and the company says it still plans to report top line results in Q3. See SA contributor Chemistfrog's rundown of BIOD's long road back from the regulatory failure of Linjeta. (PR) Comment! [Healthcare, On the Move]
Wednesday, May 8, 7:50 AM Biodel (BIOD): FQ2 EPS of -$0.37 beats by $0.06. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, February 12, 6:21 PM Biodel (BIOD): FQ1 EPS of -$0.26 beats by $0.20. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, January 24, 12:45 PM Midday top 10 gainers: JAXB +62%. NFLX +38%. SWFT +25%. TZOO +25%. HMNF +25%. CWBC +16%. YOD +16%. FDML +16%. BIOD +15%. TA +12%.
Midday top 10 Losers: OSIS -14%. CCCL -12%. WHX -12%. FBC -12%. LOCM -11%. AAPL -11%. GV -10%. SNBC -10%. SNFCA -10%. DLHC -10%. Comment! [On the Move]
Thursday, January 24, 9:28 AM Biodel (BIOD) +12.7% premarket after the biopharma company reported positive top-line results from a Phase 1 clinical trial of two ultra-rapid-acting insulin analog candidates conducted to evaluate pharmacokinetic and injection site toleration profiles relative to Humalog, a rapid-acting insulin analog. 4 Comments [Healthcare, On the Move]
Tuesday, December 18, 2012, 6:07 AM Biodel (BIOD): FQ4 EPS of -$0.42 beats by $0.04. (PR) Comment! [Earnings]
Tuesday, February 22, 2011, 5:10 PM Five potentially big gainers under $5, according to David Sterman: Biodel (BIOD), Pharmathene (PIP), Denny's (DENN), BSD Medical (BSDM), Hercules Offshore (HERO). 1 Comment
Monday, November 1, 2010, 8:19 AM Biodel (BIOD) says regulators did not approve its experimental diabetes drug, requesting instead two new late-stage trials. Shares are -50% premarket. Comment!
Monday, March 1, 2010, 9:00 AM Premarket gainers: OSIP +51%. CIIC +29%. AIG +14%. BIOD +13%. RISK +12%. MIL +11%. EP +5%. ARIA +5%. VVUS +5%. AIS +4%.
Losers: PUK -14%. GAME -13%. MXB -8%. LYG -7%. HBC -7%. RBS -7%. IRE -6%. TASR -5%. SIRI -4%. BCS -4%. AIB -4%. 2 Comments
Monday, March 1, 2010, 8:38 AM Biodel (BIOD) +15% premarket after the FDA said it would review its application seeking to market VIAject for the treatment of diabetes. VIAject is Biodel's proprietary formulation of recombinant human insulin that is designed to be absorbed into the blood faster than currently marketed rapid-acting insulin analogs. (PR) Comment!
Thursday, December 31, 2009, 9:00 AM Premarket gainers: BIOD +16%. ICXT +11%. Comment!

BIOD Biodel Inc.

BIOD

Biodel Inc.